SCHEMBL23924173

SCHEMBL23924173

O=C(Nc1cccc2cnccc12)O[C@H]1CNC[C@@H]1c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 12/20 0.49
HTT P42858 2/20 0.46
MEN1 O00255 1/20 0.46
MAPK1 P28482 1/20 0.46
BLM P54132 1/20 0.46
KMT2A Q03164 1/20 0.46
CHEK1 O14757 1/20 0.44
PIM1 P11309 1/20 0.44
CDK8 P49336 1/20 0.44
GSK3B P49841 1/20 0.44
CDK7 P50613 1/20 0.44
CDK9 P50750 1/20 0.44
LIMK1 P53667 1/20 0.44
ROCK1 Q13464 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
KDM4E B2RXH2 4/20 0.43
ALDH1A1 P00352 4/20 0.43
MAPT P10636 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924176 1.00 TRPV1 (0.49) TRPV1HTTMEN1MAPK1BLM
SCHEMBL23951601 1.00 TRPV1 (0.49) TRPV1HTTMEN1MAPK1BLM
SCHEMBL23951333 0.88 ALDH1A1 (0.47) TRPV1HTTMEN1MAPK1BLM
SCHEMBL29900607 0.88 ALDH1A1 (0.47) TRPV1HTTMEN1MAPK1BLM
SCHEMBL23951804 0.88 ALDH1A1 (0.47) TRPV1HTTMEN1MAPK1BLM
SCHEMBL23923981 0.88 ALDH1A1 (0.47) TRPV1HTTMEN1MAPK1BLM
SCHEMBL23951423 0.82 TRPV1 (0.52) TRPV1HTTMEN1MAPK1BLM
SCHEMBL23951264 0.82 TRPV1 (0.52) TRPV1HTTMEN1MAPK1BLM
SCHEMBL23951563 0.82 TRPV1 (0.52) TRPV1HTTMEN1MAPK1BLM
SCHEMBL23923921 0.82 TRPV1 (0.52) TRPV1HTTMEN1MAPK1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US claimed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US claimed
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 TRPV1 4072/4885HTT 1219/4885MEN1 4081/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 TRPV1 4072/4885HTT 1219/4885MEN1 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.